Savara (SVRA) Competitors

Savara (NASDAQ:SVRA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.

Which has more volatility and risk, SVRA or AMPH?

Savara has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Do insiders & institutionals believe in SVRA or AMPH?

87.9% of Savara shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 5.1% of Savara shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better valuation and earnings, SVRA or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$54.70M	-$0.43	-6.51
Amphastar Pharmaceuticals	$644.40M	2.69	$137.54M	$3.00	12.01

Does the media favor SVRA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Savara. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 2 mentions for Savara. Savara's average media sentiment score of 0.47 beat Amphastar Pharmaceuticals' score of 0.12 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in SVRA or AMPH?

Amphastar Pharmaceuticals received 92 more outperform votes than Savara when rated by MarketBeat users. However, 66.82% of users gave Savara an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Savara	Outperform Votes 300 66.82%	Underperform Votes 149 33.18%
Amphastar Pharmaceuticals	Outperform Votes 392 66.22%	Underperform Votes 200 33.78%

Is SVRA or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Savara's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-58.89%	-46.44%
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%

Do analysts prefer SVRA or AMPH?

Savara currently has a consensus target price of $9.86, indicating a potential upside of 252.04%. Amphastar Pharmaceuticals has a consensus target price of $60.33, indicating a potential upside of 67.45%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Amphastar Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Amphastar Pharmaceuticals beats Savara on 11 of the 17 factors compared between the two stocks.